Corrects company name in headline

** Shares of Argenica Therapeutics AGN.AX rise 3.1% to A$0.675, their highest level since Jan. 21

** Clinical drug developer announces that the Data Safety Monitoring Board recommends that trials for its drug ARG-007, continue without any changes

** ARG-007 is a drug to reduce the death of brain tissue after a stroke

** 132,174 shares change hands, 1.4 times the 30-day average

** Stock up 7.9% this month, including session's moves

(Reporting by Manasi Dasa Sundeep in Bengaluru)

((Manasi.DasaSundeep@thomsonreuters.com;))